We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Aurora Cannabis (ACB) in Q1 Earnings?
Read MoreHide Full Article
Aurora Cannabis Inc. (ACB - Free Report) is scheduled to release first-quarter fiscal 2020 results on Nov 14, after the opening bell.
Although the company has a negative average surprise of 33.3% in the trailing four quarters, it delivered a positive surprise of 100% in the last reported quarter.
Q1 Estimates
The Zacks Consensus Estimate for fiscal first-quarter earnings is pegged at a loss of 3 cents. The same for revenues is pegged at $72.8 million, indicating growth of 220.7% from the year-ago reported figure.
Factors to Influence Fiscal Q1
Increase in consumer market cannabis sales is likely to have driven the company’s cannabis net revenues in the fiscal first quarter. Increase in production from Aurora Sky and the company’s Bradford facility might have also contributed to the fiscal first-quarter performance (read more: What’s in Store for Aurora Cannabis’ Q1 Earnings?).
Aurora Cannabis has been successfully executing growth and expansion strategy, which has been driving revenue growth. In fact, in June 2019, the company announced plans for expansion of the consumer cannabis market into vapes, concentrates, and edibles. The company has plans to produce new, high-quality products across Canada in a variety of product categories through a combination of new and improved facilities.
Ongoing improvement in the company’s production cash cost per gram is likely to get reflected in gross margin on cannabis net revenues in the fiscal first quarter.
Further, the company’s medical cannabis sales are likely to reflect consistent growth with regard to patient base.
Solid increase in production, especially at Aurora Sky, is likely to have strengthened Aurora Cannabis’ position in the Canadian consumer market.
In July, the company received Health Canada licenses for outdoor cultivation at two Canadian sites – Quebec and British Columbia. These research sites have been enabling the company to develop new technology, genetics and intellectual property that has been driving sustainable, high-quality outdoor production.
However, intense competition in the medical marijuana space is likely to have affected the fiscal first-quarter performance.
Per our proven model, a combination of — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — increases the chances of an earnings beat. This is not the case here as you will see.
Earnings ESP: Aurora Cannabis has an Earnings ESP of -6.95%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Aurora Cannabis carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few stocks worth considering as they have the right combination of elements to post an earnings beat this time around.
Bank of Montreal (BMO - Free Report) has an Earnings ESP of +1.52% and a Zacks Rank #2.
Carnival Corporation (CCL - Free Report) has an Earnings ESP of +11.11% and a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
What's in the Cards for Aurora Cannabis (ACB) in Q1 Earnings?
Aurora Cannabis Inc. (ACB - Free Report) is scheduled to release first-quarter fiscal 2020 results on Nov 14, after the opening bell.
Although the company has a negative average surprise of 33.3% in the trailing four quarters, it delivered a positive surprise of 100% in the last reported quarter.
Q1 Estimates
The Zacks Consensus Estimate for fiscal first-quarter earnings is pegged at a loss of 3 cents. The same for revenues is pegged at $72.8 million, indicating growth of 220.7% from the year-ago reported figure.
Factors to Influence Fiscal Q1
Increase in consumer market cannabis sales is likely to have driven the company’s cannabis net revenues in the fiscal first quarter. Increase in production from Aurora Sky and the company’s Bradford facility might have also contributed to the fiscal first-quarter performance (read more: What’s in Store for Aurora Cannabis’ Q1 Earnings?).
Aurora Cannabis has been successfully executing growth and expansion strategy, which has been driving revenue growth. In fact, in June 2019, the company announced plans for expansion of the consumer cannabis market into vapes, concentrates, and edibles. The company has plans to produce new, high-quality products across Canada in a variety of product categories through a combination of new and improved facilities.
Ongoing improvement in the company’s production cash cost per gram is likely to get reflected in gross margin on cannabis net revenues in the fiscal first quarter.
Further, the company’s medical cannabis sales are likely to reflect consistent growth with regard to patient base.
Solid increase in production, especially at Aurora Sky, is likely to have strengthened Aurora Cannabis’ position in the Canadian consumer market.
In July, the company received Health Canada licenses for outdoor cultivation at two Canadian sites – Quebec and British Columbia. These research sites have been enabling the company to develop new technology, genetics and intellectual property that has been driving sustainable, high-quality outdoor production.
However, intense competition in the medical marijuana space is likely to have affected the fiscal first-quarter performance.
Aurora Cannabis Inc. Price and EPS Surprise
Aurora Cannabis Inc. price-eps-surprise | Aurora Cannabis Inc. Quote
What Our Quantitative Model Suggests
Per our proven model, a combination of — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — increases the chances of an earnings beat. This is not the case here as you will see.
Earnings ESP: Aurora Cannabis has an Earnings ESP of -6.95%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Aurora Cannabis carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few stocks worth considering as they have the right combination of elements to post an earnings beat this time around.
Canopy Growth Corporation (CGC - Free Report) has an Earnings ESP of +11.53% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Bank of Montreal (BMO - Free Report) has an Earnings ESP of +1.52% and a Zacks Rank #2.
Carnival Corporation (CCL - Free Report) has an Earnings ESP of +11.11% and a Zacks Rank #3.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>